Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma

Summary

This is an open-label, single arm, multicenter, Phase II clinical study to investigate the efficacy and safety profiles of autologous ATL administration in HCC patients after curative treatment. Among all the eligible patients, ratio of 7:2:1 for Stage I:II:IIIa of the HCC will be the enrolled strategy of the study to reflect the results of the previous study (Lee, Lee et al. 2015).

Timeline

Start

2022-05-14

Primary completion

2026-12-31

Completion

2027-06-30

Drugs

Indications